Метаболические основы обоснования терапии питанием при хронических заболеваниях печени
https://doi.org/10.31146/1682-8658-ecg-203-7-185-191
Аннотация
В последние 10 лет углубленное изучение процессов метаболизма при хронических заболеваниях печени и бурное развития новых технологий в производстве макро- и микронутриентов, фармаконутриентов в клинической диетологии и нутрициологии привели к созданию принципиально новых подходов в терапии питанием при этих заболеваниях. Признается тот факт, что диетические вмешательства при хронических заболеваниях печени должны следовать не только общим рекомендациям, указанным как потребность в энергии и белке, но и способствовать нормализации аминокислотного состава крови, обмена макро- и микроэлементов, витаминов и др. Особое значение приобретают методы диетической коррекции печеночной энцефалопатии, а также использования с лечебной целью микро- и фармаконутриентов.
Ключевые слова
хронические заболевания печени,
цирроз печени,
гепатит,
жировой гепатоз,
клиническая диетология,
нутрициология
Об авторах
Анатолий Михайлович Першко
ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» МО РФ
Россия
Россия
И. И. Яровенко
ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» МО РФ
Россия
Россия
В. А. Першко
ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» МО РФ
Россия
Россия
Список литературы
1. Bogush L.S. Diagnostics algorithm of iron dysbolism in patients with chronic diffusive liver desease. Health and Ecology Issues. 2008;(3):142-148. (In Russ.) @@Богуш Л. С. Алгоритм диагностики нарушений обмена железом у больных хроническими диффузными заболеваниями печени. // Проблемы здоровья и экологии. 2008, № 3. - С. 142-148.
2. Диетология. Руководство для врачей / Под редакцией А. Ю. Барановского. - 4-е издание. СПб, из-во «Питер», 2012. - 504 с.
3. Mikhtiev S.N., Mikhtieva O. A. Iron overload syndrome in chronic liver disease: focus on non-alcoholic fatty liver disease. Lechaschi Vrach Journal. 2017(17):2-7. (in Russ.) @@Михтиев С. Н., Михтиева О. А. Синдром перегрузки железом при хронических заболеваниях печени: фокус на неалкогольную жировую болезнь печени. // Лечащий врач. 2017, № 17. - С. 2-7.
4. Pershko A.M., Grinevich V. B., Ivanyuk E. S. Nutritional support in a multidisciplinary hospital. St. Petersburg, 2020. 32 p. (in Russ.) @@Першко А. М., Гриневич В. Б., Иванюк Е. С. Нутриционная поддержка в многопрофильном стационаре. - СПб, 2020. - 32 с.
5. Polunina TE, Maev IV. [Diagnosis of iron overload syndrome]. Eksp Klin Gastroenterol. 2010;(5):61-8.Russian. PMID: 20731136. @@Полунина Т. Е., Маев И. В. Диагностика синдрома перегрузки железом. // Экспериментальная и клиническая гастроэнтерология. - 2010, № 5. - С. 61-68.
6. Als-Nielsen B., Koretz R. L., Kjaergard L. L., et al. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst. Rev. 2003;(2): CD001939. doi: 10.1002/14651858.CD001939. Update in: Cochrane Database Syst Rev. 2015;2: CD001939. PMID: 12804416.
7. Bravi F., Tavani A., Bosetti C., et al. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev. 2017 Sep;26(5):368-377. doi: 10.1097/CEJ.0000000000000252
8. Bresci G., Parisi G., Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993 Aug-Sep;2(7):414-6. PMID: 8258031.
9. Carey E.J., Lai J. C., Wang C. W., et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl. 2017 May;23(5):625-633. doi: 10.1002/lt.24750
10. Chen P., Torralba M., Tan J., et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014
11. Córdoba J., López-Hellín J., Planas M., et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004 Jul;41(1):38-43. doi: 10.1016/j.jhep.2004.03.023
12. Dasarathy J., McCullough A.J., Dasarathy S. Sarcopenia in alcoholic liver disease: clinical and molecular advances. Alcohol Clin Exp Res. 2017 Aug;41(8):1419-1431. doi: 10.1111/acer.13425
13. DiCecco S.R., Wieners E. J., Wiesner R. H., Southorn P. A., et al. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc. 1989 Jan;64(1):95-102. doi: 10.1016/s0025-6196(12)65308-7
14. Dolz C., Raurich J. M., Ibanez J., et al. Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology. 1991 Mar;100(3):738-44. doi: 10.1016/0016-5085(91)80019-6
15. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019 Jan;70(1):172-193. doi: 10.1016/j.jhep.2018.06.024
16. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010 Jul;53(1):3-22. doi: 10.1016/j.jhep.2010.03.001
17. Gheorghe L., Iacob R., Vadan R., et al. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. Rom J Gastroenterol. 2005 Sep;14(3):231-8. PMID: 16200232.
18. Gluud L.L., Dam G., Borre M., et al. Oral branched chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013 Aug;143(8):1263-8. doi: 10.3945/jn.113.174375
19. Goh G.B., Chow W. C., Wang R., et al. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology. 2014 Aug;60(2):661-9. doi: 10.1002/hep.27054
20. Gow P., Spelman T., Gardner S., et al. Estimates of the Global Reduction in Liver Disease-related Mortality With Increased Coffee Consumption. Aliment Pharmacol Ther. 2020 Oct;52(7):1195-1203. doi: 10.1111/apt.16020
21. Greco A.V., Mingrone G., Benedetti G., et al. Daily energy and substrate metabolism in patients with cirrhosis. Hepatology. 1998 Feb;27(2):346-50. doi: 10.1002/hep.510270205
22. Guglielmi F.W., Panella C., Buda A., et al. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the ‘Nutritional Problems in Gastroenterology’ Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis. 2005 Sep;37(9):681-8. doi: 10.1016/j.dld.2005.03.010
23. Henkel A.S., Buchman A. L. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):202-9. doi: 10.1038/ncpgasthep0443
24. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014 Sep;61(3):642-59. doi: 10.1016/j.jhep.2014.05.042
25. Himoto T., Yoneyama H., Kurokohchi K., et al. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Nutr Res. 2011 Nov;31(11):829-35. doi: 10.1016/j.nutres.2011.09.021
26. Holecek M. Branched-chain amino acid supplementation in treatment of liver cirrhosis: Updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation. Nutrition. 2017 Sep;41:80-85. doi: 10.1016/j.nut.2017.04.003
27. Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010 May;26(5):482-90. doi: 10.1016/j.nut.2009.06.027
28. Inoue E., Hori S., Narumi Y.et al. Portalsystemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images. Radiology. 1991 May;179(2):551-5. doi: 10.1148/radiology.179.2.2014310
29. Kang Y.J., Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med. 2005 Aug-Oct;26(4-5):391-404. doi: 10.1016/j.mam.2005.07.002
30. Katayama K., Saito M., Kawaguchi T., et al. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition. 2014 Nov-Dec;30(11-12):1409-14. doi: 10.1016/j.nut.2014.04.018
31. Kawaguchi T., Izumi N., Charlton M. R., Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011 Sep 2;54(3):1063-70. doi: 10.1002/hep.24412
32. Naylor C.D., O’Rourke K., Detsky A. S., Baker J. P. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology. 1989 Oct;97(4):1033-42. doi: 10.1016/0016-5085(89)91517-5
33. Ndraha S., Hasan I., Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones. 2011 Jan;43(1):18-22. PMID: 21339541.
34. Nicoletti A., Ponziani F. R., Biolato M., et al.Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019 Sep 7;25(33):4814-4834. doi: 10.3748/wjg.v25.i33.4814
35. Nishikawa H., Enomoto H., Ishii A.et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):915-925. doi: 10.1002/jcsm.12212
36. Owen O. E. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983 Nov;72(5):1821-32. doi: 10.1172/JCI111142
37. Pace A., de Weerth A., Berna M., et al. Pancreas and liver injury are associated in individuals with increased alcohol consumption. Clin. Gastroenterol. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1241-6. doi: 10.1016/j.cgh.2009.06.010
38. Periyalwar P., Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 2012 Feb;16(1):95-131. doi: 10.1016/j.cld.2011.12.009
39. Plauth M., Cabré E., Campillo B., et al. ESPEN Guidelines on Parenteral Nutrition: Hepatology. Clin Nutr. 2009 Aug;28(4):436-44. doi: 10.1016/j.clnu.2009.04.019
40. Poole R., Kennedy O. J., Roderick P., et al. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017 Nov 22;359: j5024. doi: 10.1136/bmj.j5024. Erratum in: BMJ. 2018 Jan 12;360: k194. PMID: 29167102; PMCID: PMC5696634.
41. Qiu J., Tsien C., Thapalaya S.et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012 Oct 15;303(8): E983-93. doi: 10.1152/ajpendo.00183.2012
42. Ruhl C.E., Everhart J. E. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2005 Jan;128(1):24-32. doi: 10.1053/j.gastro.2004.09.075
43. Setiawan V.W., Wilkens L. R., Lu S. C., Hernandez B. Y., Le Marchand L, Henderson B. E. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015 Jan;148(1):118-25; quiz e15. doi: 10.1053/j.gastro.2014.10.005
44. Shergill R., Syed W., Rizvi S.A, Singh I. Nutritional support in chronic liver disease and cirrhotics. World J Hepatol. 2018 Oct 27;10(10):685-694. doi: 10.4254/wjh.v10.i10.685
45. Sinclair M., Grossmann M., Hoermann R., et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol. 2016 Nov;65(5):906-913. doi: 10.1016/j.jhep.2016.06.007
46. Takuma Y., Nouso K., Makino Y., Hayashi M., Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010 Nov;32(9):1080-90. doi: 10.1111/j.1365-2036.2010.04448.x
47. Tanaka K., Tokunaga S., Kono S., et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers.Int J Epidemiol. 1998 Jun;27(3):438-43. doi: 10.1093/ije/27.3.438
48. Torres D.M., Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology. 2013 Apr;144(4):670-2. doi: 10.1053/j.gastro.2013.02.015
49. Tsien C., Davuluri G., Singh D et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015 Jun;61(6):2018-29. doi: 10.1002/hep.27717
50. Tverdal A., Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol. 2003 Jul;13(6):419-23. doi: 10.1016/s1047-2797(02)00462-3
Рецензия
Для цитирования:
Першко А.М., Яровенко И.И., Першко В.А. Метаболические основы обоснования терапии питанием при хронических заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2022;(7):185-191. https://doi.org/10.31146/1682-8658-ecg-203-7-185-191
For citation:
Pershko A.M., Yarovenko I.I., Pershko V.A. Metabolic basis for substantiation of nutrition therapy in chronic liver diseases. Experimental and Clinical Gastroenterology. 2022;(7):185-191. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-203-7-185-191
Просмотров: 94
Послать статью по эл. почте 